论文部分内容阅读
目的探讨奥扎格雷钠与巴曲酶合用对脑梗死后脑水肿的疗效和机理及合用的安全性。方法符合入选标准的80例患者随机分组,其中治疗组44例,对照组36例。两组患者均采用常规治疗方法,治疗组加用奥扎格雷钠、巴曲酶治疗,对照组给予丹红、疏血通静滴。采用BORN-BE无创脑水肿动态监护仪测定双侧大脑半球阻抗值,同时对脑梗死发生后2,7,14d后的梗塞病灶周围水肿带面积及血液中的基质金属蛋白酶-9(MMP-9)的表达情况进行监测。结果治疗组梗塞病灶周围水肿带面积较对照组减少(P<0.01),治疗组患侧大脑半球阻抗值低于对照组(P<0.05),治疗组患者血浆中MMP-9含量在不同时段均低于对照组(P<0.05)。结论奥扎格雷钠与巴曲酶合用可有效的减少脑梗死患者脑水肿的发生,安全性较好。
Objective To investigate the efficacy and mechanism of combined use of ozagrel and batroxobin on cerebral edema after cerebral infarction and its safety. Methods Eighty patients, who met the inclusion criteria, were randomly assigned to treatment, 44 in the treatment group and 36 in the control group. Two groups of patients were treated with conventional methods, the treatment group plus sodium ozagrel, batroxobin treatment, the control group given Danhong, Shu Xue Tong intravenous infusion. The bilateral hemispheric impedance was measured by BORN-BE non-invasive brain edema dynamic monitor. The area of edema around the infarcted lesion and the expression of matrix metalloproteinase-9 (MMP-9) in the blood after 2, ) Of the expression of the monitoring. Results The area of edema around the infarcted lesion in the treatment group was decreased compared with that in the control group (P <0.01), and the hemisphere impedance in the treated group was lower than that in the control group (P <0.05). The MMP-9 levels in the plasma of patients in the treatment group were significantly higher than those in the control group Lower than the control group (P <0.05). Conclusion Ozagrel combined with batroxobin can effectively reduce the occurrence of cerebral edema in patients with cerebral infarction, and is safe.